News
8h
Zacks Investment Research on MSNPfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt SalesPfizer PFE reported first-quarter 2025 adjusted earnings per share of 92 cents, which comprehensively beat the Zacks ...
EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.
Biotech Biohaven has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results